Viral Vector and Plasmid DNA: Technologies and Global Markets
상품코드:1452908
리서치사:BCC Research
발행일:2024년 03월
페이지 정보:영문 128 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 바이러스 벡터 및 플라스미드 DNA 시장 규모는 2023년 29억 달러에서 예측 기간 동안 19.7%의 CAGR을 기록하며 2028년 말에는 71억 달러 규모로 성장할 것으로 예상됩니다.
바이러스 벡터 기술 시장은 2023년 18억 달러 규모에서 2028년 말에는 45억 달러 규모로 2028년까지 연평균 20.7% 성장할 것으로 예측됩니다. 플라스미드 DNA 기술 시장은 2023년 11억 달러에서 2028년 말까지 17.9%의 CAGR을 기록하며 26억 달러 규모로 성장할 것으로 예상됩니다.
세계의 바이러스 벡터 및 플라스미드 DNA 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 임상시험 및 특허 동향, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
제2장 시장 개요
바이러스 기술
세포 및 유전자 치료
제3장 시장 역학
시장 역학
성장 촉진요인
기회
성장 억제요인
과제
제4장 신기술과 개발
개요
바이러스 벡터 생산의 AI
Doggy Bone DNA
FRAGment Recycler : 플라스미드 DNA 합성의 신기술
특허
제조업체별 특허 보유 상황
임상시험
바이러스 벡터와 플라스미드 DNA 기술의 임상시험
제5장 세계의 바이러스 벡터 및 플라스미드 DNA 기술 시장
분류
시장 내역 : 제품 유형별
시장 내역 : 최종사용자별
연구기관
제약·바이오의약품 기업
시장 내역 : 용도별
암
유전성 질환
감염증
심혈관질환
기타 질병
지역적 내역
시장 내역 : 지역별
북미
라틴아메리카
유럽
아시아태평양
기타 지역
제6장 경쟁 정보
업계 시나리오
기업 점유율
기업 간의 경쟁 상황
경쟁 상황 : 바이러스 벡터
경쟁 상황 : 플라스미드 DNA
제7장 바이러스 벡터 및 플라스미드 DNA 기술 시장의 지속가능성 : ESG 관점
환경 요인
사회 요인
거버넌스 요인
주요 기업의 ESG 퍼포먼스
주요 기업의 ESG 퍼포먼스
Lonza : ESG 퍼포먼스
Thermo Fisher Scientific : ESG 퍼포먼스
결론
제8장 부록
조사 방법
두문자어
참고문헌
기업 개요
AGILENT TECHNOLOGIES INC.
BLUEBIRD BIO INC.
CATALENT INC.
DANAHER CORP.
FUJIFILM HOLDINGS CORP.
GENSCRIPT
GILEAD SCIENCES INC.
LONZA
NOVARTIS AG
OXFORD BIOMEDICA PLC
PLASMIDFACTORY GMBH
REGENXBIO INC.
THERMO FISHER SCIENTIFIC INC.
VGXI INC.
ksm
영문 목차
영문목차
The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.
The global market for viral vector technology is expected to grow from $1.8 billion in 2023 to $4.5 billion by the end of 2028, at a CAGR of 20.7% from 2023 through 2028.
The global market for plasmid DNA technology is expected to grow from $1.1 billion in 2023 to $2.6 billion by the end of 2028, at a CAGR of 17.9% from 2023 through 2028.
Report Scope:
The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.
The market is divided into segments and by application/industry as follows:
By product type:
Viral vector.
Plasmid DNA.
By application:
Cancer.
Genetic disorders.
Infectious diseases.
Cardiovascular diseases.
Other diseases.
By end-user:
Research institutes.
Pharmaceutical and biopharmaceutical companies.
Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.
Report Includes:
93 data tables and 47 additional tables
An overview of the global market for viral vector and plasmid DNA
Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
A look at the innovations, technological advances, and product launches from leading companies
Analysis of the industry's regulatory framework and policies, and its product pipeline
Discussion of ESG challenges and ESG practices
Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents
Profiles of the leading players in the industry
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Viral Technology
Cell and Gene Therapy
Chapter 3 Market Dynamics
Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Chapter 4 Emerging Technologies and Developments
Overview
AI in Viral Vector Production
Doggy Bone DNA
FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
Patents
Patent Holdings by Manufacturer
Clinical Trials
Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies
Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies
Segmentation Breakdown
Market Breakdown by Product Type
Market Breakdown by End User
Research Institutes
Pharmaceutical and Biopharmaceutical Companies
Market Breakdown by Application
Cancer
Genetic Disorders
Infectious Diseases
Cardiovascular Diseases
Other Diseases
Geographic Breakdown
Market Breakdown by Region
North America
Latin America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Industry Scenario
Company Shares
Competitive Landscape among Companies
Competitive Landscape in Viral Vectors
Competitive Landscape in Plasmid DNA
Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective
